QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Anders Gustavsson co-authors paper in the European Stroke Journal
Anders Gustavsson co-authored an article on the cost, quality of life and survival in patients after stroke, published in the European Stroke Journal. As expected, the study demonstrates worse outcomes for patients with worse functioning 6 months post stroke. See full article here
The Quantest – EMA relocates to Amsterdam
On Monday, November 20th, the 27 EU member states decided to relocate the EMA head office from London to Amsterdam in the Netherlands. The decision also concludes the Quantest – Quantify’s contest at ISPOR Glasgow. Amsterdam was the most popular answer to the question: “EMA is relocating after Brexit. To which city do you think EMA will relocate?” meaning the tiebreaker (How many nationalities work at Quantify) was needed […]
Poster co-authored by Quantify awarded at ISPOR Europe 2017
The poster “Risk of Major Osteoporotic Fracture (Hip, Vertebral, Radius, Humerus [MOF]) After First, Second and Third Fragility Fracture In A Swedish General Population Cohort”, co-authored by Emma Jonsson, Oskar Ström, Fredrik Borgström and Jonas Banefelt of Quantify, received ISPOR’s Research Presentation Podium and Poster Award in the category Best Poster – General at ISPOR’s 20th annual European congress in Glasgow.
The race is on: who will host the EMA?
While the UK is preparing to leave the European stage, 19 countries are lining up to host the prestigious European Medicines Agency (EMA), currently based in London. Sweden hopes to welcome the agency with its 900 employees in Stockholm, but faces fierce competition from cities like Amsterdam, Copenhagen, Lille and Vienna.
The clock is ticking, since facilities must be up and running at the new location before the actual Brexit […]